entinostat has been researched along with Colorectal Cancer in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 9.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| " To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro." | 7.76 | MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. ( Flis, K; Flis, S; Gnyszka, A; Spławiński, J, 2010) |
| "Late-stage colorectal cancer (CRC) is still a clinically challenging problem." | 5.62 | Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. ( Beyer, M; Hauzenberger, I; Heinzel, T; Kdimati, S; Krämer, OH; Lilla, S; Linnebacher, M; Maddocks, ODK; Marx, C; Marx-Blümel, L; Meyer, FB; Mullins, CS; Neri, F; Nunna, S; Piée-Staffa, A; Siniuk, K; Sonnemann, J; Thierbach, R; Wagner, T; Wang, ZQ; Westermann, M, 2021) |
| "The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC)." | 5.51 | Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. ( Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR, 2022) |
| " To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro." | 3.76 | MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. ( Flis, K; Flis, S; Gnyszka, A; Spławiński, J, 2010) |
| "Late-stage colorectal cancer (CRC) is still a clinically challenging problem." | 1.62 | Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. ( Beyer, M; Hauzenberger, I; Heinzel, T; Kdimati, S; Krämer, OH; Lilla, S; Linnebacher, M; Maddocks, ODK; Marx, C; Marx-Blümel, L; Meyer, FB; Mullins, CS; Neri, F; Nunna, S; Piée-Staffa, A; Siniuk, K; Sonnemann, J; Thierbach, R; Wagner, T; Wang, ZQ; Westermann, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Zhang, Y | 1 |
| Jiang, Y | 1 |
| Wu, J | 1 |
| Inks, ES | 1 |
| Chou, CJ | 1 |
| Gao, S | 1 |
| Hou, J | 1 |
| Ding, Q | 1 |
| Li, J | 1 |
| Wang, X | 1 |
| Huang, Y | 1 |
| Xu, W | 1 |
| Karasic, TB | 1 |
| Brown, TJ | 1 |
| Schneider, C | 1 |
| Teitelbaum, UR | 1 |
| Reiss, KA | 1 |
| Mitchell, TC | 1 |
| Massa, RC | 1 |
| O'Hara, MH | 1 |
| DiCicco, L | 1 |
| Garcia-Marcano, L | 1 |
| Amaravadi, RK | 1 |
| O'Dwyer, PJ | 1 |
| Marx, C | 1 |
| Sonnemann, J | 1 |
| Beyer, M | 1 |
| Maddocks, ODK | 1 |
| Lilla, S | 1 |
| Hauzenberger, I | 1 |
| Piée-Staffa, A | 1 |
| Siniuk, K | 1 |
| Nunna, S | 1 |
| Marx-Blümel, L | 1 |
| Westermann, M | 1 |
| Wagner, T | 1 |
| Meyer, FB | 1 |
| Thierbach, R | 1 |
| Mullins, CS | 1 |
| Kdimati, S | 1 |
| Linnebacher, M | 1 |
| Neri, F | 1 |
| Heinzel, T | 1 |
| Wang, ZQ | 1 |
| Krämer, OH | 1 |
| Kim, K | 1 |
| Skora, AD | 1 |
| Li, Z | 1 |
| Liu, Q | 1 |
| Tam, AJ | 1 |
| Blosser, RL | 1 |
| Diaz, LA | 1 |
| Papadopoulos, N | 1 |
| Kinzler, KW | 1 |
| Vogelstein, B | 1 |
| Zhou, S | 1 |
| Azad, NS | 1 |
| El-Khoueiry, A | 1 |
| Yin, J | 1 |
| Oberg, AL | 1 |
| Flynn, P | 1 |
| Adkins, D | 1 |
| Sharma, A | 1 |
| Weisenberger, DJ | 1 |
| Brown, T | 1 |
| Medvari, P | 1 |
| Jones, PA | 1 |
| Easwaran, H | 1 |
| Kamel, I | 1 |
| Bahary, N | 1 |
| Kim, G | 1 |
| Picus, J | 1 |
| Pitot, HC | 1 |
| Erlichman, C | 1 |
| Donehower, R | 1 |
| Shen, H | 1 |
| Laird, PW | 1 |
| Piekarz, R | 1 |
| Baylin, S | 1 |
| Ahuja, N | 1 |
| Flis, S | 2 |
| Gnyszka, A | 2 |
| Spławiński, J | 2 |
| Flis, K | 1 |
| Zhan, Y | 1 |
| Gong, K | 1 |
| Chen, C | 1 |
| Wang, H | 1 |
| Li, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer[NCT03215264] | Phase 1 | 20 participants (Actual) | Interventional | 2017-10-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants were evaluable for toxicity if they have taken one dose of HCQ and one dose of entinostat. To be considered for evaluability in a Phase I cohort in the absence of dose-limiting toxicity, patients should have completed > 85% of HCQ doses, and at least 3 of 4 entinostat doses. The MTD will be defined as a) the dose producing DLT in 1 out of 6 patients, or b) the dose level below the dose which produced DLT in ≥ 2 out of 3 patients, or in ≥ 2 out of 6 patients. DLTs will be defined by toxicity occurring during the first 4 weeks of this study. (NCT03215264)
Timeframe: 18 months
| Intervention | mg (Number) | |
|---|---|---|
| Hydroxychloroquine Daily | Entinostat weekly | |
| All Participants | 1200 | 5 |
2 trials available for entinostat and Colorectal Cancer
| Article | Year |
|---|---|
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colorectal Neop | 2022 |
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Line, Tum | 2017 |
6 other studies available for entinostat and Colorectal Cancer
| Article | Year |
|---|---|
Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Colon; Colorectal Neoplasms; HCT116 | 2017 |
Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells.
Topics: Acetylation; Animals; Apoptosis; Benzamides; Colorectal Neoplasms; Humans; Irinotecan; Mice; Pyridin | 2021 |
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
Topics: Animals; Antibodies, Monoclonal; Azacitidine; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Co | 2014 |
HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dr | 2009 |
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colo | 2010 |
P38 MAP kinase functions as a switch in MS-275-induced reactive oxygen species-dependent autophagy and apoptosis in human colon cancer cells.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; B | 2012 |